Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

1.

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.

Moore RA, Derry S, Makinson GT, McQuay HJ.

Arthritis Res Ther. 2005;7(3):R644-65. Epub 2005 Mar 24. Review. Erratum in: Arthritis Res Ther. 2006;8(1):401.

PMID:
15899051
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.

PMID:
18405470
[PubMed - indexed for MEDLINE]
Free Article
4.

Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.

Mallen SR, Essex MN, Zhang R.

Curr Med Res Opin. 2011 Jul;27(7):1359-66. doi: 10.1185/03007995.2011.581274. Epub 2011 May 12. Review.

PMID:
21561397
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

Edwards JE, McQuay HJ, Moore RA.

Pain. 2004 Oct;111(3):286-96. Review.

PMID:
15363872
[PubMed - indexed for MEDLINE]
6.

Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.

Matheson AJ, Figgitt DP.

Drugs. 2001;61(6):833-65. Review.

PMID:
11398914
[PubMed - indexed for MEDLINE]
7.

Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.

Niculescu L, Li C, Huang J, Mallen S.

Curr Med Res Opin. 2009 Mar;25(3):729-40. doi: 10.1185/03007990802714382 .

PMID:
19210159
[PubMed - indexed for MEDLINE]
8.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
[PubMed - indexed for MEDLINE]
9.

Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports.

Moore RA, Derry S, McQuay HJ.

Arthritis Res Ther. 2008;10(3):R53. doi: 10.1186/ar2422. Epub 2008 May 8.

PMID:
18466615
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.

[No authors listed]

Prescrire Int. 2001 Apr;10(52):46-9.

PMID:
11718158
[PubMed - indexed for MEDLINE]
11.

Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.

McKenna F, Arguelles L, Burke T, Lefkowith J, Geis GS.

Clin Exp Rheumatol. 2002 Jan-Feb;20(1):35-43.

PMID:
11892706
[PubMed - indexed for MEDLINE]
12.

Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

McCormack PL.

Drugs. 2011 Dec 24;71(18):2457-89. doi: 10.2165/11208240-000000000-00000. Review.

PMID:
22141388
[PubMed - indexed for MEDLINE]
13.

The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.

Maetzel A, Krahn M, Naglie G.

Arthritis Rheum. 2003 Jun 15;49(3):283-92.

PMID:
12794781
[PubMed - indexed for MEDLINE]
Free Article
14.

Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.

Ashcroft DM, Chapman SR, Clark WK, Millson DS.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):829-34. Review.

PMID:
11485128
[PubMed - indexed for MEDLINE]
15.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
[PubMed - indexed for MEDLINE]
16.

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

Clemett D, Goa KL.

Drugs. 2000 Apr;59(4):957-80. Review. Erratum in: Drugs 2001;61(4):498.

PMID:
10804043
[PubMed - indexed for MEDLINE]
17.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
[PubMed - indexed for MEDLINE]
18.

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.

Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G; SUCCESS-I Investigators.

Am J Med. 2006 Mar;119(3):255-66. Erratum in: Am J Med. 2006 Sep;119(9):801.

PMID:
16490472
[PubMed - indexed for MEDLINE]
19.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.

Clin Ther. 2005 Aug;27(8):1196-214. Review.

PMID:
16199245
[PubMed - indexed for MEDLINE]
20.

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS.

Lancet. 1999 Dec 18-25;354(9196):2106-11.

PMID:
10609815
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk